PeerView Oncology

 

PeerView Oncology
Avatar

41 y/o Female With Newly Diagnosed EGFR+ Stage 4 NSCLC and Brain Mets: Which EGFR TKIs to Consider and How to Combine Them?

By PeerView Oncology FEATURING Sandip Patel, Manmeet Ahluwalia, Kathryn Beal
By PeerView Oncology FEATURING Sandip Patel, Manmeet Ahluwalia, Kathryn Beal
0 views
May 28, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

03:38
Lilly Medical Affairs

SERDS: Relevance and Role in Current & Future Treatments for HR+…

Feat. K. Jhaveri
Lung
17:03
PeerView Oncology

Challenging Case of a 63 y/o Never-Smoking Female With TTF-1+ Lung A…

Feat. E. Garon, J. Heymach
15:20
PeerView Oncology

Locally Advanced and Early NSCLC IO Update: Will IO Change the Multi…

Feat. B. Stiles
15:18
PeerView Oncology

Managing EGFR+ NSCLC With CNS Metastases: Is There a Difference in C…

Feat. S. Patel
02:22
PeerView Oncology

45 y/o With EGFR+ NSCLC and Brain Mets: Should We Consider Mono or C…

Feat. S. Patel, M. Ahluwalia, K. Beal
05:24
PeerView Oncology

64 y/o Female With Newly Diagnosed Stage 4 NSCLC, EGFR exon 19 Mutat…

Feat. S. Patel, M. Ahluwalia, K. Beal
17:21
PeerView Oncology

Management of EGFR-Mutant Lung Cancer With Central Nervous System Me…

Feat. S. Patel, M. Ahluwalia, K. Beal
04:37
PeerView Oncology

41 y/o Female With Newly Diagnosed EGFR+ Stage 4 NSCLC and Brain Met…

Feat. S. Patel, M. Ahluwalia, K. Beal